IL6 and neoplasm: STAT3 has a role in tumor immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-κB (NF-κB) and interleukin-6 (IL-6)–GP130–Janus kinase (JAK) pathways [42], however, the non-canonical NFκB pathway regulated STAT3 dependent MDSC activity needs further investigation[43–45].